ReWalk Robotics (RWLK) Stock Price, News & Analysis

Company Overview

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions in the United States, Europe, the Asia-Pacific, and Africa. The company offers ReWalk Personal and ReWalk Rehabilitation for spinal cord injuries and everyday use by paraplegic individuals at home and in communities; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment; and MyoCycle and MediTouch tutor movement biofeedback devices for use at home or in clinic. It markets and sells its products directly to third party payers; institutions, including rehabilitation centers; and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Ilit, Israel.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.64 to $1.25
• 52-Week Range: N/A
• Volume: 303,600 shs
• Average Volume: 541,468 shs
• Market Capitalization: $63.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RWLK Stock Analysis - Frequently Asked Questions

How were ReWalk Robotics' earnings last quarter?

ReWalk Robotics Ltd. (NASDAQ:RWLK) issued its earnings results on Thursday, November, 11th. The medical device company reported ($0.06) EPS for the quarter, hitting analysts' consensus estimates of ($0.06). The medical device company had revenue of $1.97 million for the quarter, compared to analyst estimates of $1.60 million. ReWalk Robotics had a negative net margin of 238.35% and a negative trailing twelve-month return on equity of 29.00%.

What other stocks do shareholders of ReWalk Robotics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ReWalk Robotics investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), NVIDIA (NVDA), Meta Platforms (META) and NovoCure (NVCR).

Company Calendar

• Last Earnings: 11/11/2021
• Today: 11/19/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: NASDAQ:RWLK
• CUSIP: N/A
• CIK: 1607962
• Web: www.rewalk.com
• Phone: (724) 959-0123
• Fax: N/A
• Employees: 56
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-19,570,000.00
• Net Margins: -238.35%
• Pretax Margin: -233.51%
• Return on Equity: -29.00%
• Return on Assets: -25.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.47
• Quick Ratio: 2.99

Sales & Book Value

• Annual Sales: $5.51 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.10 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 60,030,000
• Free Float: 58,764,000
• Market Cap: $63.04 million
• Optionable: Optionable
• Beta: 2.30